Recent developments in retroviral-mediated gene transduction

Molecular Therapy

Volumn 2, Issue 5, 2000, Pages 423-434

  Daly, Gordon ^a   Chernajovsky, Yuti ^a,b  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b SBRLSMD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE RECEPTOR; MESSENGER RNA;

CELL LINE; GENE EXPRESSION REGULATION; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; METABOLISM; PATHOGENICITY; PLASMID; REGULATORY SEQUENCE; RETROPOSON; RETROVIRUS; REVIEW; TRANSGENE; VIRION; VIROLOGY;

CELL LINE; GENE EXPRESSION REGULATION; GENETIC VECTORS; PLASMIDS; RECEPTORS, CELL SURFACE; REGULATORY SEQUENCES, NUCLEIC ACID; RETROELEMENTS; RETROVIRIDAE; RNA, MESSENGER; TRANSDUCTION, GENETIC; TRANSGENES; VIRION; VIROLOGY;

EID: 0034320712     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1006/mthe.2000.0211     Document Type: Review

References (127)

1. Miller, A. D. (1990). Retrovirus packaging cells. Hum. Gene Ther. 1(1): 5-14.
2. Vile, R. G., and Russell, S. J. (1995). Retroviruses as vectors. Br. Med. Bull. 51(1): 12-30.
3. Klimatcheva, E., Rosenblatt, J. D., and Planelles, V. (1999). Lentiviral vectors and gene therapy. Front. Biosci. 4(1): 481-496.
4. Lynch, C. M., and Miller, A. D. (1991). Production of high-titer helper virus-free retro-viral vectors by cocultivation of packaging cells with different host ranges. J. Virol. 65(7): 3887-3890.
5. Cosset, F. L., Girod, A., Flamant, F., Drynda, A., Ronfort, C., Valsesia, S., Molina, R. M., Faure, C., Nigon, V. M., and Verdier, G. (1993). Use of helper cells with two host ranges to generate high-titer retroviral vectors. Virology 193: 385-395.
6. Kim, Y., Lim, H., and Kim, K. (1998). Production of high-titer retroviral vectors and detection of replication-competent retroviruses. Mol. Cells: 36-42.
7. Burns, J. C., Friedmann, T., Driever, W., Burrascano, M., and Yee, J. K. (1993). Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: Concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells [see comments]. Proc. Natl. Acad. Sci. USA 90(17): 8033-8037.
8. Lee, S. G., Kim, S., Robbins, P. D., and Kim, B. G. (1996). Optimization of environmental factors for the production and handling of recombinant retrovirus. Appl. Microbiol. Biotechnol. 45(4): 477-483.
9. Sharma, S., Murai, F., Miyanohara, A., and Friedmann, T. (1997). Noninfectious virus-like particles produced by Moloney murine leukemia virus-based retrovirus packaging cells deficient in viral envelope become infectious in the presence of lipofection reagents. Proc. Natl. Acad. Sci. USA 94(20): 10803-10808.
10. Rigg, R. J., Chen, J., Dando, J. S., Forestell, S. P., Plavec, I., and Bohnlein, E. (1996). A novel human amphotropic packaging cell line: High titer, complement resistance, and improved safety. Virology 218: 290-295.
11. Takeuchi, Y., Porter, C. D., Strahan, K. M., Preece, A. F., Gustafsson, K., Cosset, F. L., Weiss, R. A., and Collins, M. K. (1996). Sensitization of cells and retroviruses to human serum by (alpha 1-3) galactosyltransferase. Nature 379(6560): 85-88.
12. DePolo, N. J., Harkleroad, C. E., Bodner, M., Watt, A. T., Anderson, C. G., Greengard, J. S., Murthy, K. K., Dubensky, T. J., and Jolly, D. J. (1999). The resistance of retroviral vectors produced from human cells to serum inactivation in vivo and in vitro is primate species dependent. J. Virol. 73(8): 6708-6714.
13. Gerin, P. A., Gilligan, M. G., Searle, P. F., and Al, R. M. (1999). Improved titers of retroviral vectors from the human FLYRD18 packaging cell line in serum-and protein-free medium. Hum. Gene Ther. 10(12): 1965-1974.
14. Arai, T., Takada, M., Ui, M., and Iba, H. (1999). Dose-dependent transduction of vesicular stomatitis virus G protein-pseudotyped retrovirus vector into human solid tumor cell lines and murine fibroblasts. Virology 260: 109-115.
15. Cavazzana-Calvo, M., Hacein-Bey, S., de Saint Basile, G., Gross, F., Yvon, E., Nusbaum, P., Selz, F., Hue, C., Ceratin, S., Casanova, J.-L., Bousso, P., Le deist, F., and Fischer, A. (2000). Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288: 669-672.
16. Chen, S. T., Iida, A., Guo, L., Friedmann, T., and Yee, J. K. (1996). Generation of packaging cell lines for pseudotyped retroviral vectors of the G protein of vesicular stomatitis virus by using a modified tetracycline inducible system. Proc. Natl. Acad. Sci. USA 93(19): 10057-10062.
17. Ory, D. S., Neugeboren, B. A., and Mulligan, R. C. (1996). A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. Proc. Natl. Acad. Sci. USA 93(21): 11400-11406.
18. DePolo, N. J., Reed, J. D., Sheridan, P. L., Townsend, K., Sauter, S. L., Jolly, D. J., and Dubensky, T. W. J. (2000). VSV-G pseudotyped lentiviral vector particles produced in human cells are inactivated by human serum. Mol. Ther. 2: 218-222.
19. Spiegel, M., Bitzer, M., Schenk, A., Rossmann, H., Neubert, W. J., Seidler, U., Gregor, M., and Lauer, U. (1998). Pseudotype formation of Moloney murine leukemia virus with Sendai virus glycoprotein F. J. Virol. 72: 5296-5302.
20. Yee, J. K., Miyanohara, A., LaPorte, P., Bouic, K., Burns, J. C., and Friedmann, T. (1994). A general method for the generation of high-titer, pantropic retroviral vectors: Highly efficient infection of primary hepatocytes. Proc. Natl. Acad. Sci. USA 91(20): 9564-9568.
21. Schnierle, B. S., Stitz, J., Bosch, V., Nocken, F., Merget, M. H., Engelstadter, M., Kurth, R., Groner, B., and Cichutek, K. (1997). Pseudotyping of murine leukemia virus with the envelope glycoproteins of HIV generates a retroviral vector with specificity of infection for CD4-expressing cells. Proc. Natl. Acad. Sci. USA 94(16): 8640-8645.
22. Lindemann, D., Bock, M., Schweizer, M., and Rethwilm, A. (1997). Efficient pseudo-typing of murine leukemia virus particles with chimeric human foamy virus envelope proteins. J. Virol 71(6): 4815-4820.
23. Marandin, A., Dubart, A., Pflumio, F., Cosset, F., Cordette, V., Chapel-Fernandes, S., Coulombel, L., Vainchenker, W., and Louache, F. (1998). Retrovirus-mediated gene transfer into human CD34+38low primitive cells capable of reconstituting long-term cultures in vitro and nonobese diabetic-severe combined immunodeficiency mice in vivo. Hum. Gene Ther. 9: 1497-1511.
24. Landau, N. R., and Littman, D. R. (1992). Packaging system for rapid production of murine leukemia virus vectors with variable tropism. J. Virol. 66(8): 5110-5113.
25. Pear, W. S., Nolan, G. P., Scott, M. L., and Baltimore, D. (1993). Production of high-titer helper-free retroviruses by transient transfection. Proc. Natl. Acad. Sci. USA 90(18): 8392-8396.
26. Finer, M. H., Dull, T. J., Qin, L., Farson, D., and Roberts, M. R. (1994). kat: A high-efficiency retroviral transduction system for primary human T lymphocytes. Blood 83(1): 43-50.
27. Faustinella, F., Kwon, H., Serrano, F., Belmont, J. W., Caskey, C. T., and Aguilar, C. E. (1994). A new family of murine retroviral vectors with extended multiple cloning sites for gene insertion. Hum. Gene Ther. 5(3): 307-312.
28. Berberich, S. L., and Stoltzfus, C. M. (1991). Mutations in the regions of the Rous sarcoma virus 3′ splice sites: Implications for regulation of alternative splicing. J. Virol. 65(5): 2640-2646.
29. Emerman, M., and Temin, H. M. (1984). Genes with promoters in retrovirus vectors can be independently suppressed by an epigenetic mechanism. Cell, 449-467.
30. Emerman, M., and Temin, H. M. (1986). Comparison of promoter suppression in avian and murine retrovirus vectors. Nucleic Acids Res. 14(23): 9381-9396.
31. Vile, R., Miller, N., Chernajovsky, Y., and Hart, I. (1994). A comparison of the properties of different retroviral vectors containing the murine tyrosinase promoter to achieve transcriptionally targeted expression of the HSVtk or IL-2 genes. Gene Ther. 1(5): 307-316.
32. Salmons, B., and Gunzburg, W. H. (1993). Targeting of retroviral vectors for gene therapy. Hum. Gene Ther. 4(2): 129-141.
33. Correll, P. H., Colilla, S., and Karlsson, S. (1994). Retroviral vector design for long-term expression in murine hematopoietic cells in vivo. Blood 84(6): 1812-1822.
34. Moullier, P., Bohl, D., Cardoso, J., Heard, J. M., and Danos, O. (1995). Long-term delivery of a lysosomal enzyme by genetically modified fibroblasts in dogs. Nat. Med. 1(4): 353-357.
35. Berlioz, C., and Darlix, J. L. (1995). An internal ribosomal entry mechanism promotes translation of murine leukemia virus gag polyprotein precursors. J. Virol. 69(4): 2214-2222.
36. Vagner, S., Waysbort, A., Marenda, M., Gensac, M. C., Amalric, F., and Prats, A. C. (1995). Alternative translation initiation of the Moloney murine leukemia virus mRNA controlled by internal ribosome entry involving the p57/PTB splicing factor. J. Biol. Chem. 270(35): 20376-20383.
37. Gurtu, V., Yan, G., and Zhang, G. (1996). IRES bicistronic expression vectors for efficient creation of stable mammalian cell lines. Biochem. Biophys. Res. Commun. 229: 295-298.
38. Sokolic, R. A., Sekhsaria, S., Sugimoto, Y., Whiting, T. N., Linton, G. F., Li, F., Gottesman, M. M., and Malech, H. L. (1996). A bicistronic retrovirus vector containing a picornavirus internal ribosome entry site allows for correction of X-linked CGD by selection for MDR1 expression. Blood 87(1): 42-50.
39. Saleh, M. (1997). A retroviral vector that allows efficient co-expression of two genes and the versatility of alternate selection markers. Hum. Gene Ther. 8(8): 979-983.
40. Ghattas, I. R., Sanes, J. R., and Majors, J. E. (1991). The encephalomyocarditis virus internal ribosome entry site allows efficient coexpression of two genes from a recombinant provirus in cultured cells and in embryos. Mol. Cell. Biol. 11(12): 5848-5859.
41. Ramesh, N., Kim, S. T., Wei, M. Q., Khalighi, M., and Osborne, W. R. (1996). High-titer bicistronic retroviral vectors employing foot-and-mouth disease virus internal ribosome entry site. Nucleic Acids Res. 24(14): 2697-2700.
42. Borman, A. M., Bailly, J. L., Girard, M., and Kean, K. M. (1995). Picornavirus internal ribosome entry segments: Comparison of translation efficiency and the requirements for optimal internal initiation of translation in vitro. Nucleic Acids Res. 23(18): 3656-3663.
43. Wei, C. M., Lowy, D. R., and Scolnick, E. M. (1980). Mapping of transforming region of the Harvey murine sarcoma virus genome by using insertion-deletion mutants constructed in vitro. Proc. Natl. Acad. Sci. USA 77(8): 4674-4678.
44. Berlioz, C., Torrent, C., and Darlix, J. L. (1995). An internal ribosomal entry signal in the rat VL30 region of the Harvey murine sarcoma virus leader and its use in dicistronic retroviral vectors. J. Virol. 69(10): 6400-6407.
45. Howk, R. S., Troxler, D. H., Lowy, D., Duesberg, P. H., and Scolnick, E. M. (1978). Identification of a 3OS RNA with properties of a defective type C virus in murine cells. J. Virol. 25(1): 115-123.
46. Keshet, E., Shaul, Y., Kaminchik, J., and Aviv, H. (1980). Heterogeneity of "virus-like" genes encoding retrovirus-associated 30S RNA and their organization within the mouse genome. Cell 20(2): 431-439.
47. French, N. S., and Norton, J. D. (1997). Structure and functional properties of mouse VL30 retrotransposons. Biochim. Biophys. Acta 1352(1): 33-47.
48. Harvey, J. J. (1964). An unidentified virus which causes the rapid production of tumours in mice. Nature (London) 204: 1104-1105.
49. Kirsten, W. H., and Mayer, L. A. (1967). Morphologic responses to a murine erythroblastosis virus. J. Natl. Cancer Inst. 39: 311-335.
50. Firulli, B. A., Anderson, G. R., Stoler, D. L., and Estes, S. D. (1993). Anoxia-inducible rat VL30 elements and their relationship to ras-containing sarcoma viruses. J. Virol. 67(11): 6857-6862.
51. Estes, S. D., Stoler, D. L., and Anderson, G. R. (1995). Anoxic induction of a sarcoma virus-related VL30 retrotransposon is mediated by a cis-acting element which binds hypoxia-inducible factor 1 and an anoxia-inducible factor. J. Virol. 69(10): 6335-6341.
52. Chakraborty, A. K., Zink, M. A., Boman, B. M., and Hodgson, C. P. (1993). Synthetic retrotransposon vectors for gene therapy. FASEB J. 7(10): 971-977.
53. French, N. S., and Norton, J. D. (1995). Construction of a retroviral vector incorporating mouse VL30 retrotransposon-derived, transcriptional regulatory sequences. Anal. Biochem. 228: 354-355.
54. Chakraborty, A. K., Zink, M. A., and Hodgson, C. P. (1995). Expression of VL30 vectors in human cells that are targets for gene therapy. Biochem. Biophys. Res. Commun. 209: 677-683.
55. Metz, M. Z., Best, D. M., and Kane, S. E. (1995). Harvey murine sarcoma virus/MDR1 retroviral vectors: Efficient virus production and foreign gene transduction using MDR1 as a selectable marker. Virology 208: 634-643.
56. Torrent, C., Gabus, C., and Darlix, J. L. (1994). A small and efficient dimerization/packaging signal of rat VL30 RNA and its use in murine leukemia virus-VL30-derived vectors for gene transfer. J. Virol. 68(2): 661-667.
57. Torrent, C., Wang, P., and Darlix, J. L. (1992). A murine leukemia virus derived retroviral vector with a rat VL30 packaging psi sequence. Bone Marrow Transplant. 1(143): 143-147.
58. Torrent, C., Berlioz, C., and Darlix, J. L. (1996). Stable MLV-VL30 dicistronic retroviral vectors with a VL30 or MoMLV sequence promoting both packaging of genomic RNA and expression of the 3′ cistron. Hum. Gene Ther. 7(5): 603-612.
59. Chong, H., and Vile, R. G. (1996). Replication-competent retrovirus produced by a 'split-function' third generation amphotropic packaging cell line. Gene Ther. 3(7): 624-629.
60. Martinez, I., and Dornburg, R. (1996). Partial reconstitution of a replication-competent retrovirus in helper cells with partial overlaps between vector and helper cell genomes. Hum. Gene Ther. 7(6): 705-712.
61. Dougherty, J. P., and Temin, H. M. (1987). A promoterless retroviral vector indicates that there are sequences in U3 required for 3′ RNA processing. Proc. Natl. Acad. Sci. USA 84(5): 1197-1201.
62. Olson, P., Nelson, S., and Dornburg, R. (1994). Improved self-in activating retroviral vectors derived from spleen necrosis virus. J. Virol. 68(11): 7060-7066.
63. Niwa, O., Yokota, Y., Ishida, H., and Sugahara, T. (1983). Independent mechanisms involved in suppression of the Moloney leukemia virus genome during differentiation of murine teratocarcinoma cells. Cell 32(4): 1105-1113.
64. Stewart, C. L., Stuhlmann, H., Jahner, D., and Jaenisch, R. (1982). De novo methylation, expression, and infectivity of retroviral genomes introduced into embryonal carcinoma cells. Proc. Natl. Acad. Sci. USA 79(13): 4098-4102.
65. Gautsch, J. W., and Wilson, M. C. (1983). Delayed de novo methylation in teratocarcinoma suggests additional tissue-specific mechanisms for controlling gene expression. Nature 301 (5895): 32-37.
66. Palmer, T. D., Rosman, G. J., Osborne, W. R., and Miller, A. D. (1991). Genetically modified skin fibroblasts persist long after transplantation but gradually inactivate introduced genes. Proc. Natl. Acad. Sci. USA 88(4): 1330-1334.
67. Tsukiyama, T., Ueda, H., Hirose, S., and Niwa, O. (1992). Embryonal long terminal repeat-binding protein is a murine homolog of FTZ-F1, a member of the steroid receptor super-family. Mol. Cell. Biol. 12(3): 1286-1291.
68. Hilberg, F., Stocking, C., Ostertag, W., and Grez, M. (1987). Functional analysis of a retroviral host-range mutant: Altered long terminal repeat sequences allow expression in embryonal carcinoma cells. Proc. Natl. Acad. Sci. USA 84(15): 5232-5236.
69. Petersen, R., Kempler, G., and Barklis, E. (1991). A stem cell-specific silencer in the primer-binding site of a retrovirus. Mol. Cell. Biol. 11(3): 1214-1221.
70. Loh, T. P., Sievert, L. L., and Scott, R. W. (1988). Negative regulation of retrovirus expression in embryonal carcinoma cells mediated by an intragenic domain. J. Virol. 62(11): 4086-4095.
71. Vernet, M., and Cebrian, J. (1996). Cis-acting elements that mediate the negative regulation of Moloney murine leukemia virus in mouse early embryos. J. Virol. 70(8): 5630-5633.
72. Flanagan, J. R., Becker, K. G., Ennist, D. L., Gleason, S. L., Driggers, P. H., Levi, B. Z., Appella, E., and Ozato, K. (1992). Cloning of a negative transcription factor that binds to the upstream conserved region of Moloney murine leukemia virus. Mol. Cell. Biol. 12(1): 38-44.
73. Challita, P. M., Skelton, D., el, K. A., Yu, X. J., Weinberg, K., and Kohn, D. B. (1995). Multiple modifications in as elements of the long terminal repeat of retroviral vectors lead to increased expression and decreased DNA methylation in embryonic carcinoma cells. J. Virol. 69(2): 748-755.
74. Richards, C. A., and Huber, B. E. (1993). Generation of a transgenic model for retrovirus-mediated gene therapy for hepatocellular carcinoma is thwarted by the lack of transgene expression. Hum. Gene Ther. 4(2): 143-150.
75. Bednarik, D. P. (1993). DNA methylation and retrovirus expression. Exs 64(300): 300-329.
76. Lange, C., and Blankenstein, T. (1997). Loss of retroviral gene expression in bone marrow reconstituted mice correlates with down-regulation of gene expression in long-term culture initiating cells. Gene Ther. 4(4): 303-308.
77. Cedar, H. (1988). DNA methylation and gene activity. Cell 53(1): 3-4.
78. Boyes, J., and Bird, A. (1991). DNA methylation inhibits transcription indirectly via a methyl-CpG binding protein. Cell 64(6): 1123-1134.
79. Szyf, M., Tanigawa, G., and McCarthy, P. J. (1990). A DNA signal from the Thy-1 gene defines de novo methylation patterns in embryonic stem cells. Mol. Cell. Biol. 10(8): 4396-4400.
80. Sauer, B., and Henderson, N. (1988). Site-specific DNA recombination in mammalian cells by the Cre recombinase of bacteriophage P1. Proc. Natl. Acad. Sci. USA 85(14): 5166-5170.
81. Russ, A. P., Friedel, C., Grez, M., and von, M. H. (1996). Self-deleting retrovirus vectors for gene therapy. J. Virol. 70(8): 4927-4932.
82. Couture, L. A., Mullen, C. A., and Morgan, R. A. (1994). Retroviral vectors containing chimeric promoter/enhancer elements exhibit cell-type-specific gene expression. Hum. Gene Ther. 5(6): 667-677.
83. Bentley, N. J., Eisen, T., and Goding, C. R. (1994). Melanocyte-specific expression of the human tyrosinase promoter: Activation by the microphthalmia gene product and role of the initiator. Mol. Cell. Biol. 14(12): 7996-8006.
84. Siders, W. M., Halloran, P. J., and Fenton, R. G. (1996). Transcriptional targeting of recombinant adenoviruses to human and murine melanoma cells. Cancer Res. 56(24): 5638-5646.
85. Diaz, R. M., Eisen, T., Hart, I. R., and Vile, R. G. (1998). Exchange of viral promoter/enhancer elements with heterologous regulatory sequences generates targeted hybrid long terminal repeat vectors for gene therapy of melanoma. J. Virol. 72(1): 789-795.
86. Russell, S. J., Hawkins, R. E., and Winter, G. (1993). Retroviral vectors displaying functional antibody fragments. Nucleic Acids Res. 21(5): 1081-1085.
87. Cosset, F. L., Morling, F. J., Takeuchi, Y., Weiss, R. A., Collins, M. K., and Russell, S. J. (1995). Retroviral retargeting by envelopes expressing an N-terminal binding domain. J. Virol. 69(10): 6314-6322.
88. Maurice, M., Mazur, S., Bullough, F. J., Salvetti, A., Collins, M. K., Russell, S. J., and Cosset, F. L. (1999). Efficient gene delivery to quiescent interleukin-2 (IL-2)-dependent cells by murine leukemia virus-derived vectors harboring IL-2 chimeric envelope glycoproteins. Blood 94: 401-410.
89. Valsesia, W. S., Morling, F. J., Nilson, B. H., Takeuchi, Y., Russell, S. J., and Cosset, F. L. (1996). Improvement of retroviral retargeting by using amino acid spacers between an additional binding domain and the N terminus of Moloney murine leukemia virus SU. J. Virol. 70(3): 2059-2064.
90. Yarranton, G. T. (1992). Inducible vectors for expression in mammalian cells. Curr. Opin. Biotechnol. 3(5): 506-511.
91. Gossen, M., and Bujard, H. (1992). Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl. Acad. Sci. USA 89(12): 5547-5551.
92. Hofmann, A., Nolan, G. P., and Blau, H. M. (1996). Rapid retroviral delivery of tetracycline-inducible genes in a single autoregulatory cassette. Proc. Natl. Acad. Sci. USA 93(11): 5185-5190.
93. Gill, G., and Ptashne, M. (1988). Negative effect of the transcriptional activator GAL4. Nature 334(6184): 721-724.
94. Ptashne, M., and Gann, A. A. (1990). Activators and targets. Nature 346(6282): 329-331.
95. Shockett, P., Difilippantonio, M., Hellman, N., and Schatz, D. G. (1995). A modified tetracycline-regulated system provides autoregulatory, inducible gene expression in cultured cells and transgenic mice. Proc. Natl. Acad. Sci. USA 92(14): 6522-6526.
96. Iida, A., Chen, S. T., Friedmann, T., and Yee, J. K. (1996). Inducible gene expression by retrovirus-mediated transfer of a modified tetracycline-regulated system. J. Virol. 70(9): 6054-6059.
97. Gossen, M., Freundlieb, S., Bender, G., Muller, G., Hillen, W., and Bujard, H. (1995). Transcriptional activation by tetracyclines in mammalian cells. Science 268(5218): 1766-1769.
98. Watsuji, T., Okamoto, Y., Emi, N., Katsuoka, Y., and Hagiwara, M. (1997). Controlled gene expression with a reverse tetracycline-regulated retroviral vector (RTRV) system. Biochem. Biophys. Res. Commun. 234: 769-773.
99. Lindemann, D., Patriquin, E., Feng, S., and Mulligan, R. C. (1997). Versatile retrovirus vector systems for regulated gene expression in vitro and in vivo. Mol. Med. 3(7): 466-476.
100. Li, K. J., and Garoff, H. (1998). Packaging of intron-containing genes into retrovirus vectors by alphavirus vectors. Proc. Natl. Acad. Sci. USA 95(7): 3650-3654.
101. Wahlfors, J. J., Xanthopoulos, K. G., and Morgan, R. A. (1997). Semliki Forest virus-mediated production of retroviral vector RNA in retroviral packaging cells. Hum. Gene Ther. 8(17): 2031-2041.
102. Bilbao, G., Feng, M., Rancourt, C., Jackson, W. J., and Curiel, D. T. (1997). Adenoviral/retroviral vector chimeras: a novel strategy to achieve high-efficiency stable transduction in vivo. FASEB J. 11(8): 624-634.
103. Feng, M., Jackson, W. J., Goldman, C. K., Rancourt, C., Wang, M., Dusing, S. K., Siegal, G., and Curiel, D. T. (1997). Stable in vivo gene transduction via a novel adenoviral/retroviral chimeric vector [see comments]. Nat. Biotechnol. 15(9): 866-870.
104. Noguiez, H. P., Meur, M. R., Salzmann, J. L., and Klatzmann, D. (1996). Plasmoviruses: Nonviral/viral vectors for gene therapy. Proc. Natl. Acad. Sci. USA 93(9): 4175-4180.
105. Frankel, A. D., and Young, J. A. (1998). HIV-1: Fifteen proteins and an RNA. Annu. Rev. Biochem. 67(1): 1-25.
106. Coffin, J. M., Hughes, S. H., and Varmus, H. E. (1997) In Retroviruses. Cold Spring Harbor Laboratory Press, New York.
107. Naldini, L., Blomer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F. H., Verma, I. M., and Trono, D. (1996). In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272(5259): 263-267.
108. Buchschacher, G. J., and Panganiban, A. T. (1992). Human immunodeficiency virus vectors for inducible expression of foreign genes. J. Virol. 66(5): 2731-2739.
109. Richardson, J. H., Kaye, J. F., Child, L. A., and Lever, A. M. (1995). Helper virus-free transfer of human immunodeficiency virus type 1 vectors. J. Gen. Virol., 691-696.
110. Berkowitz, R. D., Hammarskjold, M. L., Helga, M. C., Rekosh, D., and Goff, S. P. (1995). 5′ regions of HIV-1 RNAs are not sufficient for encapsidation: Implications for the HIV-1 packaging signal. Virology 212: 718-723.
111. Kaye, J. F., Richardson, J. H., and Lever, A. M. (1995). Cis-acting sequences involved in human immunodeficiency virus type 1 RNA packaging. J. Virol. 69(10): 6588-6592.
112. Gorlich, D., and Mattaj, I. W. (1996). Nucleocytoplasmic transport. Science 271(5255): 1513-1518.
113. Vodicka, M. A., Koepp, D. M., Silver, P. A., and Emerman, M. (1998). HIV-1 Vpr interacts with the nuclear transport pathway to promote macrophage infection. Genes Dev. 12(2): 175-185.
114. Klimkait, T., Strebel, K., Hoggan, M. D., Martin, M. A., and Orenstein, J. M. (1990). The human immunodeficiency virus type 1-specific protein vpu is required for efficient virus maturation and release. J. Virol. 64(2): 621-629.
115. Gottlinger, H. G., Dorfman, T., Cohen, E. A., and Haseltine, W. A. (1993). Vpu protein of human immunodeficiency virus type 1 enhances the release of capsids produced by gag gene constructs of widely divergent retroviruses. Proc. Natl. Acad. Sci. USA 90(15): 7381-7385.
116. Miller, M. D., Warmerdam, M. T., Gaston, I., Greene, W. C., and Feinberg, M. B. (1994). The human immunodeficiency virus-1 nef gene product: a positive factor for viral infection and replication in primary lymphocytes and macrophages. J. Exp. Med. 179(1): 101-113.
117. Spina, C. A., Kwoh, T. J., Chowers, M. Y., Guatelli, J. C., and Richman, D. D. (1994). The importance of nef in the induction of human immunodeficiency virus type 1 replication from primary quiescent CD4 lymphocytes. J. Exp. Med. 179(1): 115-123.
118. Aiken, C., and Trono, D. (1995). Nef stimulates human immunodeficiency virus type 1 proviral DNA synthesis. J. Virol. 69(8): 5048-5056.
119. Schwartz, O., Marechal, V., Danos, O., and Heard, J. M. (1995). Human immunodeficiency virus type 1 Nef increases the efficiency of reverse transcription in the infected cell. J. Virol. 69(7): 4053-4059.
120. Chowers, M. Y., Pandori, M. W., Spina, C. A., Richman, D. D., and Guatelli, J. C. (1995). The growth advantage conferred by HIV-1 nef is determined at the level of viral DNA formation and is independent of CD4 downregulation. Virology 212: 451-457.
121. Zufferey, R., Nagy, D., Mandel, R. J., Naldini, L., and Trono, D. (1997). Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat. Biotechnol. 15(9): 871-875.
122. Aiken, C. (1997). Pseudotyping human immunodeficiency virus type 1 (HIV-1) by the glycoprotein of vesicular stomatitis virus targets HIV-1 entry to an endocytic pathway and suppresses both the requirement for Nef and the sensitivity to cyclosporin A. J. Virol. 71(8): 5871-5877.
123. Dull, T., Zufferey, R., Kelly, M., Mandel, R. J., Nguyen, M., Trono, D., and Naldini, L (1998). A third-generation lentivirus vector with a conditional packaging system. J. Virol. 72(11): 8463-8471.
124. Wei, P., Garber, M. E., Fang, S. M., Fischer, W. H., and Jones, K. A. (1998). A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell 92(4): 451-462.
125. Zufferey, R., Dull, T., Mandel, R. J., Bukovsky, A., Quiroz, D., Naldini, L., and Trono, D. (1998). Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J. Virol. 72(12): 9873-9880.
126. Bukrinsky, M. I., and Haffar, O. K. (1999). HIV-1 nuclear import: In search of a leader. Front. Biosci. 4: 772-781.
127. Swain, A., and Coffin, J. M. (1989). Polyadenylation at correct sites in genome RNA is not required for retrovirus replication or genome encapsidation. J. Virol. 63(8): 3301-3306.